title: Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON).
abstract: A method to obtain the optimal selection criteria, taking into account available resources and capacity and the impact on power, is presented for the Dutch-Belgian randomised lung cancer screening trial (NELSON). NELSON investigates whether 16-detector multi-slice computed tomography screening will decrease lung cancer mortality compared to no screening. A questionnaire was sent to 335,441 (mainly) men, aged 50-75. Smoking exposure (years smoked, cigarettes/day, years quit) was determined, and expected lung cancer mortality was estimated for different selection scenarios for the 106,931 respondents, using lung cancer mortality data by level of smoking exposure (US Cancer Prevention Study I and II). Selection criteria were chosen so that the required response among eligible subjects to reach sufficient sample size was minimised and the required sample size was within our capacity. Inviting current and former smokers (quit <or= 10 years ago) who smoked >15 cigarettes/day during >25 years or >10 cigarettes/day during >30 years was most optimal. With a power of 80%, 17,300-27,900 participants are needed to show a 20-25% lung cancer mortality reduction 10 years after randomisation. Until October 18, 2005 11,103 (first recruitment round) and 4,325 (second recruitment round) (total = 15,428) participants have been randomised. Selecting participants for lung cancer screening trials based on risk estimates is feasible and helpful to minimize sample size and costs. When pooling with Danish trial data (n = +/-4,000) NELSON is the only trial without screening in controls that is expected to have 80% power to show a lung cancer mortality reduction of at least 25% 10 years after randomisation.
authors.affiliation: Department of Public Health, Erasmus MC, Rotterdam, The Netherlands. c.vaniersel@erasmusmc.nl
authors.forename: Carola A
authors.initials: CA
authors.lastname: van Iersel
authors.forename: Harry J
authors.initials: HJ
authors.lastname: de Koning
authors.forename: Gerrit
authors.initials: G
authors.lastname: Draisma
authors.forename: Willem P T M
authors.initials: WP
authors.lastname: Mali
authors.forename: Ernst Th
authors.initials: ET
authors.lastname: Scholten
authors.forename: Kristiaan
authors.initials: K
authors.lastname: Nackaerts
authors.forename: Mathias
authors.initials: M
authors.lastname: Prokop
authors.forename: J Dik F
authors.initials: JD
authors.lastname: Habbema
authors.forename: Mathijs
authors.initials: M
authors.lastname: Oudkerk
authors.forename: Rob J
authors.initials: RJ
authors.lastname: van Klaveren
mesh_terms: D000368:Aged; D001530:Belgium / Q000453:epidemiology; D002985:Clinical Protocols; D035061:Control Groups; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000517:prevention & control; D008297:Male; D008403:Mass Screening; D008875:Middle Aged; D009367:Neoplasm Staging; D009426:Netherlands / Q000453:epidemiology; D018579:Patient Selection; D012307:Risk Factors; D018401:Sample Size; D014057:Tomography, X-Ray Computed